US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6908757B1
(en)
|
1998-03-26 |
2005-06-21 |
The Procter & Gamble Company |
Serine protease variants having amino acid deletions and substitutions
|
SI1077722T1
(sl)
|
1998-05-22 |
2007-02-28 |
Ottawa Health Research Inst |
Metode in produkti za induciranje sluznicne imunosti
|
DK1079857T3
(da)
|
1998-05-29 |
2007-01-29 |
Novartis Vaccines & Diagnostic |
Meningitidis B/C-kombinationsvacciner
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
JP4812942B2
(ja)
*
|
1999-02-26 |
2011-11-09 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
CGモチーフを含むオリゴヌクレオチドを用いるNeisseria抗原殺菌活性の増強
|
DE60038166T2
(de)
*
|
1999-03-19 |
2009-03-12 |
Glaxosmithkline Biologicals S.A., Rixensart |
Impfstoff gegen bakterielle antigene
|
WO2000061612A2
(en)
|
1999-04-02 |
2000-10-19 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
HU229255B1
(en)
|
1999-04-19 |
2013-10-28 |
Smithkline Beecham Biolog |
Vaccines
|
EP1171158A2
(en)
*
|
1999-04-20 |
2002-01-16 |
SmithKline Beecham Biologicals s.a. |
Vaccine comprising rsv antigen and cpg oligonucleotide
|
CA2376992A1
(en)
*
|
1999-06-29 |
2001-01-04 |
Smithkline Beecham Biologicals S.A. |
Use of cpg as an adjuvant for hiv vaccine
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
EP1210415A2
(en)
|
1999-07-22 |
2002-06-05 |
The Procter & Gamble Company |
Subtilisin protease variants having amino acid substitutions in defined epitope regions
|
US6946128B1
(en)
|
1999-07-22 |
2005-09-20 |
The Procter & Gamble Company |
Protease conjugates having sterically protected epitope regions
|
CN1373802A
(zh)
|
1999-07-22 |
2002-10-09 |
宝洁公司 |
在特定表位区域具有氨基酸缺失和取代的枯草杆菌蛋白酶变体
|
CZ2002171A3
(cs)
|
1999-07-22 |
2002-06-12 |
The Procter & Gamble Company |
Proteinázový konjugát, čistící prostředek a prostředek osobní péče
|
CA2380947C
(en)
|
1999-08-19 |
2011-11-01 |
Dynavax Technologies Corporation |
Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
|
GB9925559D0
(en)
*
|
1999-10-28 |
1999-12-29 |
Smithkline Beecham Biolog |
Novel method
|
US7223398B1
(en)
|
1999-11-15 |
2007-05-29 |
Dynavax Technologies Corporation |
Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
|
GB9928196D0
(en)
|
1999-11-29 |
2000-01-26 |
Chiron Spa |
Combinations of B, C and other antigens
|
AU5615601A
(en)
|
2000-02-23 |
2001-09-03 |
Smithkline Beecham Biolog |
Novel compounds
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US20020098199A1
(en)
|
2000-03-10 |
2002-07-25 |
Gary Van Nest |
Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
|
US20010046967A1
(en)
|
2000-03-10 |
2001-11-29 |
Gary Van Nest |
Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
|
US7157437B2
(en)
|
2000-03-10 |
2007-01-02 |
Dynavax Technologies Corporation |
Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
|
US20030129251A1
(en)
|
2000-03-10 |
2003-07-10 |
Gary Van Nest |
Biodegradable immunomodulatory formulations and methods for use thereof
|
US7129222B2
(en)
|
2000-03-10 |
2006-10-31 |
Dynavax Technologies Corporation |
Immunomodulatory formulations and methods for use thereof
|
EP2192128A3
(en)
|
2000-04-21 |
2010-09-22 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
AUPQ761200A0
(en)
*
|
2000-05-19 |
2000-06-15 |
Hunter Immunology Limited |
Compositions and methods for treatment of mucosal infections
|
JP5004261B2
(ja)
|
2000-05-19 |
2012-08-22 |
コリクサ コーポレイション |
単糖類及び二糖類に基づく化合物を用いた感染症及び他の疾患の予防的並びに治療的な処置
|
ATE442866T1
(de)
|
2000-06-20 |
2009-10-15 |
Corixa Corp |
Fusionsproteine aus mycobakterium tuberculosis
|
CZ20024154A3
(cs)
|
2000-06-26 |
2003-08-13 |
Stressgen Biotechnologies Corporation |
Použití prostředku obsahujícího napojený protein pro výrobu farmaceutického přípravku pro léčení bradavic a chorob a stavů souvisejících s papiloma virem
|
EP1319069B1
(en)
|
2000-06-28 |
2008-05-21 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
DE60142410D1
(de)
|
2000-12-27 |
2010-07-29 |
Dynavax Tech Corp |
Immunomodulatorische polynukleotide und verfahren zur deren verwendung
|
WO2002089747A2
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
US7255868B2
(en)
|
2001-06-21 |
2007-08-14 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same—I
|
CA2456328C
(en)
|
2001-08-07 |
2015-05-26 |
Dynavax Technologies Corporation |
Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof
|
BR0212619A
(pt)
|
2001-09-20 |
2004-08-17 |
Glaxo Group Ltd |
Sequência de nucleotìdeo, vetor, proteìna, composição farmacêutica, dispositivo de liberação intradérmica, método para tratar um paciente que sofre de uma doença ou é suscetìvel a ela, uso de uma sequência de nucleotìdeo, e, processo para a produção de um nucleotìdeo
|
ES2405790T3
(es)
|
2001-12-17 |
2013-06-03 |
Corixa Corporation |
Composiciones y métodos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
|
CA2388049A1
(en)
|
2002-05-30 |
2003-11-30 |
Immunotech S.A. |
Immunostimulatory oligonucleotides and uses thereof
|
CN1650012A
(zh)
|
2002-07-24 |
2005-08-03 |
英特塞尔股份公司 |
来自致病病毒的备选阅读框所编码的抗原
|
EP1537418A2
(en)
|
2002-09-13 |
2005-06-08 |
Intercell AG |
Method for isolating hepatitis c virus peptides
|
PT2241325E
(pt)
|
2002-10-29 |
2012-04-12 |
Coley Pharm Gmbh |
Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
|
JP2006512927A
(ja)
|
2002-12-11 |
2006-04-20 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
5’cpg核酸およびその使用方法
|
KR100525321B1
(ko)
*
|
2002-12-13 |
2005-11-02 |
안웅식 |
파필로마바이러스 항원 단백질 및CpG-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물
|
US8158768B2
(en)
|
2002-12-23 |
2012-04-17 |
Dynavax Technologies Corporation |
Immunostimulatory sequence oligonucleotides and methods of using the same
|
ATE442376T1
(de)
|
2002-12-23 |
2009-09-15 |
Dynavax Tech Corp |
Oligonukleotide mit einer immunsystemstimulierenden sequenz und verfahren zu deren anwendung
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
BRPI0406628A
(pt)
|
2003-01-06 |
2005-12-06 |
Corixa Corp |
Determinados compostos de fosfato de aminoalquil glucosaminida e seu uso
|
CN100355453C
(zh)
*
|
2003-03-24 |
2007-12-19 |
英特塞尔股份公司 |
改进的疫苗
|
EP1608402B1
(en)
|
2003-03-24 |
2010-10-20 |
Intercell AG |
Improved vaccines
|
KR100872472B1
(ko)
*
|
2003-05-15 |
2008-12-05 |
도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 |
면역자극제
|
JP2007528838A
(ja)
*
|
2003-12-24 |
2007-10-18 |
ライデン ユニバーシティ メディカル センター |
腫瘍特異的ワクチンとしての合成タンパク質
|
AU2005285513B2
(en)
|
2004-05-25 |
2011-02-24 |
Oregon Health And Science University |
SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
|
US8846051B2
(en)
|
2004-10-08 |
2014-09-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention |
Modulation of replicative fitness by deoptimization of synonymous codons
|
WO2006104890A2
(en)
|
2005-03-31 |
2006-10-05 |
Glaxosmithkline Biologicals Sa |
Vaccines against chlamydial infection
|
PL2457926T3
(pl)
|
2005-04-29 |
2015-03-31 |
Glaxosmithkline Biologicals Sa |
Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis
|
EP1981905B1
(en)
|
2006-01-16 |
2016-08-31 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Chlamydia vaccine
|
CN101421306B
(zh)
*
|
2006-04-19 |
2013-09-18 |
浦项工科大学校产学协力团 |
用于治疗和预防子宫颈癌的包含hpv多肽和免疫增强肽的组合物
|
AU2007345768B2
(en)
*
|
2006-07-27 |
2013-08-01 |
Ligocyte Pharmaceuticals, Inc. |
Chimeric influenza virus-like particles
|
WO2008094200A2
(en)
*
|
2006-07-27 |
2008-08-07 |
Ligocyte Pharmaceuticals, Inc |
Chimeric virus-like particles
|
US8486414B2
(en)
|
2007-04-04 |
2013-07-16 |
Infectious Disease Research Institute |
Immunogenic compositions comprising Mycobacterium tuberculosis polypeptides and fusions thereof
|
US8518903B2
(en)
|
2007-04-19 |
2013-08-27 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Use of toll-like receptor-9 agonists
|
AR066405A1
(es)
|
2007-04-20 |
2009-08-19 |
Glaxosmithkline Biolog Sa |
Vacuna
|
PE20090281A1
(es)
|
2007-05-24 |
2009-03-28 |
Glaxosmithkline Biolog Sa |
Composicion antigenica liofilizada
|
JP2008308474A
(ja)
*
|
2007-06-18 |
2008-12-25 |
Nitto Denko Corp |
抗原ペプチド製剤の調製方法
|
ES2725450T3
(es)
|
2007-07-02 |
2019-09-24 |
Etubics Corp |
Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
|
BRPI0820270A2
(pt)
|
2007-11-07 |
2015-06-16 |
Celldex Therapeutics Inc |
Anticorpo monoclonal, vetor de expressão, célula, conjugado molecular, composição, uso da composição, método para detectar a presença ou ausência de dec-205 em uma amostra biológica, e, uso de um conjugado molecular.
|
JP5711972B2
(ja)
|
2007-12-24 |
2015-05-07 |
アイディー バイオメディカル コーポレイション オブ ケベック |
組換えrsv抗原
|
MX2011005915A
(es)
|
2008-12-03 |
2011-08-17 |
Proyecto Biomedicina Cima Sl |
Uso de modulinas solubles en fenol para el desarrollo de vacunas.
|
CA2653478A1
(en)
*
|
2009-01-23 |
2010-07-23 |
Gregg Martin |
Automated wash system for industrial vehicles
|
CA2757620C
(en)
*
|
2009-04-30 |
2016-04-26 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
WO2010149743A2
(en)
|
2009-06-24 |
2010-12-29 |
Id Biomedical Corporation Of Quebec |
Vaccine
|
US9492531B2
(en)
|
2009-06-24 |
2016-11-15 |
Glaxosmithkline Biologicals Sa |
Recombinant RSV vaccines
|
BR112012001666A2
(pt)
|
2009-07-15 |
2019-09-24 |
Novartis Ag |
composições de proteína rsv f e métodos para fazer as mesmas
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
JP5917402B2
(ja)
|
2009-11-03 |
2016-05-11 |
タケダ ヴァクシーンズ, インコーポレイテッド |
キメラRSV−Fポリペプチド、およびレンチウイルスGagまたはアルファレトロウイルスGagに基づくVLP
|
WO2011101332A1
(en)
|
2010-02-16 |
2011-08-25 |
Proyecto De Biomedicina Cima, S.L. |
Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
|
NZ602892A
(en)
|
2010-04-13 |
2014-08-29 |
Celldex Therapeutics Inc |
Antibodies that bind human cd27 and uses thereof
|
US10668092B2
(en)
|
2010-09-24 |
2020-06-02 |
The John Hopkins University |
Compositions and methods for treatment of inflammatory disorders
|
US9072760B2
(en)
|
2010-09-24 |
2015-07-07 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
|
US20130345079A1
(en)
|
2010-10-27 |
2013-12-26 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
EP2637687B1
(en)
|
2010-11-08 |
2021-01-06 |
Infectious Disease Research Institute |
Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
|
TWI507413B
(zh)
*
|
2010-11-15 |
2015-11-11 |
Nat Health Research Institutes |
脂質化多抗原表位疫苗
|
EP3593813A1
(en)
|
2010-12-14 |
2020-01-15 |
GlaxoSmithKline Biologicals S.A. |
Mycobacterium antigenic composition
|
WO2012088425A2
(en)
|
2010-12-22 |
2012-06-28 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
|
EP2505640A1
(en)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Vaccine compositions for birnavirus-borne diseases
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
US20150030586A1
(en)
|
2011-06-21 |
2015-01-29 |
Sarah Ellen Warren |
Compositions and methods for the therapy and diagnosis of cancer
|
CN102343103B
(zh)
*
|
2011-07-26 |
2016-04-27 |
马丁 |
人乳头状瘤病毒16型三肽疫苗的筛选和验证及持续表达hpv16 e5, e6, e7的肿瘤动物模型的构建
|
EP2666785A1
(en)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Complement component C5a-based vaccine
|
BR112015002483A2
(pt)
|
2012-08-03 |
2017-11-07 |
Infectious Disease Res Inst |
composições e métodos para o tratamento de uma infecção ativa por mycobacterium tuberculosis
|
CA2879939A1
(en)
|
2012-08-06 |
2014-02-13 |
Glaxosmithkline Biologicals S.A. |
Novel method
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
WO2014031178A1
(en)
|
2012-08-24 |
2014-02-27 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
EP2703483A1
(en)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
PCSK9 peptide vaccine
|
WO2014052453A1
(en)
*
|
2012-09-25 |
2014-04-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Oral therapy of necrotizing enterocolitis
|
EP3586870A1
(en)
|
2013-03-12 |
2020-01-01 |
The Trustees Of The University Of Pennsylvania |
Improved vaccines for human papilloma virus and methods for using the same
|
RU2761631C2
(ru)
|
2013-03-13 |
2021-12-13 |
Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз |
Белки rsv в предшествующей слиянию конформации и их применение
|
EP3608332B1
(en)
|
2013-03-15 |
2022-06-01 |
GlaxoSmithKline Biologicals SA |
Vaccine against human rhinovirus
|
EP2978447B1
(en)
|
2013-03-28 |
2019-05-08 |
Infectious Disease Research Institute |
Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
|
EP3030260A1
(en)
|
2013-08-05 |
2016-06-15 |
GlaxoSmithKline Biologicals S.A. |
Combination immunogenic compositions
|
EP2952893A1
(en)
|
2014-06-04 |
2015-12-09 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Method for detecting antibody-secreting B cells specific for HLA
|
CA2951430A1
(en)
|
2014-06-13 |
2015-12-17 |
Glaxosmithkline Biologicals Sa |
Immunogenic combinations
|
AU2015252119A1
(en)
|
2014-11-07 |
2016-05-26 |
Takeda Vaccines, Inc. |
Hand, foot, and mouth vaccines and methods of manufacture and use thereof
|
AR102547A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
|
PT3233912T
(pt)
|
2014-12-19 |
2021-08-09 |
Regenesance B V |
Antocorpos que se ligam a c6 humano e utilizações destes
|
AU2016205215B2
(en)
|
2015-01-09 |
2021-03-11 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
AU2015384786B2
(en)
|
2015-03-03 |
2020-08-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Display platform from bacterial spore coat proteins
|
WO2016145085A2
(en)
|
2015-03-09 |
2016-09-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
US11149087B2
(en)
|
2015-04-20 |
2021-10-19 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
BR112017025316A2
(pt)
|
2015-05-26 |
2018-07-31 |
Ohio State Innovation Foundation |
estratégia de vacina baseada em nanopartículas contra o vírus da gripe suína
|
CN106543272A
(zh)
*
|
2015-09-18 |
2017-03-29 |
江苏众红生物工程创药研究院有限公司 |
多功能标签融合蛋白及其表达方法和应用
|
US10865244B2
(en)
|
2016-04-18 |
2020-12-15 |
Celldex Therapeutics, Inc. |
Nucleic acids encoding agonistic antibodies that bind CD40
|
EP3458088A2
(en)
|
2016-05-21 |
2019-03-27 |
Infectious Disease Research Institute |
Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
|
AU2017268822B2
(en)
|
2016-05-27 |
2020-03-26 |
Etubics Corporation |
Neoepitope vaccine compositions and methods of use thereof
|
WO2018053294A1
(en)
|
2016-09-16 |
2018-03-22 |
Infectious Disease Research Institute |
Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
CA3043790A1
(en)
|
2016-12-16 |
2018-06-21 |
Institute For Research In Biomedicine |
Novel recombinant prefusion rsv f proteins and uses thereof
|
WO2018162450A1
(en)
|
2017-03-06 |
2018-09-13 |
Fundación Para La Investigación Médica Aplicada |
New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
|
SG11201909265QA
(en)
|
2017-04-19 |
2019-11-28 |
Inst Res Biomedicine |
Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
|
KR20240096685A
(ko)
|
2017-06-15 |
2024-06-26 |
액세스 투 어드밴스드 헬스 인스티튜트 |
나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
|
WO2019035963A1
(en)
|
2017-08-16 |
2019-02-21 |
Ohio State Innovation Foundation |
NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
|
CA3081578A1
(en)
|
2017-11-03 |
2019-05-09 |
Takeda Vaccines, Inc. |
Zika vaccines and immunogenic compositions, and methods of using the same
|
WO2019147925A1
(en)
|
2018-01-26 |
2019-08-01 |
Nantcell, Inc. |
Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
|
KR20210011919A
(ko)
|
2018-04-17 |
2021-02-02 |
셀덱스 쎄라퓨틱스, 인크. |
항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
|
WO2020016322A1
(en)
|
2018-07-19 |
2020-01-23 |
Glaxosmithkline Biologicals Sa |
Processes for preparing dried polysaccharides
|
CN110004150B
(zh)
*
|
2018-08-01 |
2023-03-10 |
中国农业科学院兰州兽医研究所 |
一种具有免疫增强活性的CpG寡聚核苷酸序列及其应用
|
WO2020051766A1
(zh)
|
2018-09-11 |
2020-03-19 |
上海市公共卫生临床中心 |
一种广谱抗流感疫苗免疫原及其应用
|
CN109675028A
(zh)
*
|
2019-03-01 |
2019-04-26 |
龙阔(苏州)生物工程有限公司 |
疫苗佐剂及其制备方法和应用及猪繁殖与呼吸综合征疫苗
|
CN109985234A
(zh)
*
|
2019-04-12 |
2019-07-09 |
南华大学 |
一种梅毒螺旋体dna疫苗及其应用
|
AU2021207701A1
(en)
*
|
2020-01-17 |
2022-09-15 |
Bill & Melinda Gates Foundation |
Multivalent Streptococcus vaccines
|
CN114075293B
(zh)
*
|
2020-08-14 |
2022-11-15 |
长沙诺盟生物医药有限公司 |
包含突变的hpv16 e6蛋白的融合蛋白和疫苗组合物
|
AU2021337493A1
(en)
|
2020-09-04 |
2023-05-18 |
Access To Advanced Health Institute |
Co-lyophilized rna and nanostructured lipid carrier
|
IL307519A
(en)
|
2021-04-09 |
2023-12-01 |
Celldex Therapeutics Inc |
Antibodies against ILT4, anti-ILT4\PD-L1 bispecific antibody and their uses
|
WO2023077521A1
(en)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Anti-ilt4 and anti-pd-1 bispecific constructs
|
WO2023114727A1
(en)
|
2021-12-13 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacteriophage lambda-vaccine system
|
WO2024052882A1
(en)
|
2022-09-09 |
2024-03-14 |
Access To Advanced Health Institute |
Immunogenic vaccine composition incorporating a saponin
|
WO2024186635A2
(en)
|
2023-03-03 |
2024-09-12 |
Celldex Therapeutics, Inc. |
Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
|